Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
P/E ratio for Bachem Holding AG (BANB.SW)
P/E ratio as of 2023: 43.40
According to Bachem Holding AG's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 43.40. At the end of 2022 the company had a P/E ratio of 58.48.
P/E ratio history for Bachem Holding AG from 2002 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 43.40 |
| 2022 | 58.48 |
| 2021 | 88.46 |
| 2020 | 70.92 |
| 2019 | 39.54 |
| 2018 | 33.37 |
| 2017 | 50.04 |
| 2016 | 29.69 |
| 2015 | 22.06 |
| 2014 | 22.78 |
| 2013 | 27.74 |
| 2012 | 32.05 |
| 2011 | 46.54 |
| 2010 | 26.65 |
| 2009 | 96.84 |
| 2008 | 91.91 |
| 2007 | 99.40 |
| 2006 | 26.01 |
| 2005 | 25.37 |
| 2004 | 133.76 |
| 2003 | 112.68 |
| 2002 | 129.31 |